Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies

As TSC-101 is advanced toward a pivotal trial, which is expected to begin later this year, Cellares’ manufacturing platform is being evaluated as a scalable and economical path to future demand.

The post Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies appeared first on GEN - Genetic Engineering and Biotechnology News.